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ABSTRACT – NMDA receptor (NMDA-R) antagonists are extensively used as schizoph-
renia models due to their ability to evoke positive and negative symptoms as well as cog-
nitive deficits similar to those of the illness. Likewise, 5-HT2A receptor agonists display
hallucinogen actions resembling psychotic symptoms. Overall, these drugs are useful mo-
dels of schizophrenia for the screening of new antipsychotic drugs. However, the cellular
and network elements involved in these actions are poorly known. Data obtained by several
groups in recent years indicate that the prefrontal cortex (PFC) and anatomically related
areas play a major role in these actions. This paper summarizes data obtained by the authors
supporting that a) NMDA-R antagonists (phencyclidine –PCP–, dizocilpine –MK–801–)
and 5-HT2A agonists (DOI) alter the function of PFC in a similar fashion, and b) antipsy-
chotic drugs exert their therapeutic action, at least in part, by normalizing hyperactivity
states in PFC. While the actions of NMDA-R antagonists may involve blockade of these
receptors in PFC and subcortical areas, that of antipsychotic drugs, in particular atypical
drugs like clozapine, appear to be mediated essentially by a local action in PFC. These re-
sults help to better understand the neurobiological basis of the action of pharmacological
models of schizophrenia and the mode of action of antipsychotic drugs.
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Introduction
The present report summarizes data ob-
tained in recent years in one of the main re-
search lines (antidepressants, antipsy-
chotics, brain circuits) carried out by the
“Systems Neuropharmacology” group of
CIBERSAM.
Schizophrenia is associated with alter-
ations in the anatomy and function of sever-
al cortical and subcortical areas. Among
these, the prefrontal cortex (PFC) seems to
play a key role in the pathophysiology of
the illness1,2. Despite the obvious difficulty
in modeling these alterations in experimen-
tal models of the illness, non-competitive
N-methyl-D-aspartate (NMDA) receptor
(antagonists such as the dissociative anaes-
thetics ketamine and phencyclidine (PCP)
and MK-801 (dizocilpine), have been ex-
tensively used as pharmacological models
of schizophrenia due to their ability to
evoke positive and negative symptoms of
schizophrenia as well as the cognitive
deficits of the illness in humans. These
agents elicit a potent behavioural syndrome
as well as cognitive and sensory deficits in
experimental animals that resemble human
schizophrenia symptoms (see Geyer et al.3;
Krystal et al.4 for review). NMDA receptor
antagonists also induce schizophrenia
symptoms in healthy subjects and aggravate
them in schizophrenic patients. Further-
more, the behavioural effects of NMDA re-
ceptor antagonists are sensitive to the treat-
ment with antipsychotic drugs that alleviate
psychotic symptoms in schizophrenic pa-
tients4. Also, serotonergic agents such as ly-
sergic acid diathylamine and related com-
pounds, which are agonists of 5-HT2A
receptors, can produce perceptual and psy-
chic alterations5. DOI (1-[2,5-dimethoxy-4-
iodophenyl-2-aminopropane]) is a partial 5-
HT2A/2C agonist that evokes long-lasting al-
terations in consciousness and perception.
DOI acts by over stimulating 5-HT2A recep-
tors, since its behavioral, neurochemical
and electrophysiological effects are blocked
by the selective 5-HT2A receptor antagonist
M100907.
To provide a deeper insight of the brain
areas and neuronal types affected by NMDA-
R antagonists and DOI, we have conducted a
series of electrophysiological, histological
and neurochemical studies to examine the
cellular and population responses of PFC,
paying also a special attention to the potential
reversal of these actions by conventional and
second generation (atypical) antipsychotic
drugs.
Methods
Animals. Adult male Wistar rats (250-300
g) (Iffa Credo; Lyon, France) were been
used in most experiments. We also used 10-
15 weeks old male homozygous 5-HT1A re-
ceptor knockouts (5-HT1A -/-, referred on-
wards as KO) and wild-type (5-HT1A +/+,
referred onwards as WT) mice of the same
genetic background (C57BL/6). Animal
procedures were performed according to the
European Union regulations (O.J. of E.C.
L358/1 18/12/1986) for the use of laborato-
ry animals and were approved by the Insti-
tutional Animal Care and Use Committee.
Electrophysiological experiments. We ex-
amined the effect of psychotomimetic drugs
such as the NMDA receptor antagonist
phencyclicine (PCP), the preferential 5-
HT2A receptor agonist DOI (both with hal-
lucinogen properties) and the antipsychotic
drugs clozapine and haloperidol on the ac-
tivity of PFC, assessed by a) single unit ex-
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Figure 1. Representative spectrograms showing the effects of the administration of phencyclidine (PCP, 0.25 mg/kg i.v.)
and clozapine (CLZ, 1 mg/kg i.v.) on low frequency oscillations recorded in mPFC. Note the marked reduction in the
power spectrum induced by CPP (middle panel) and the reversal produced by CLZ. Abscissa is in s, ordinate is in Hz. 
The intensity of the power spectrum is color-coded (red = high intensity; blue = low intensitiy). Redrawn from data in
Kargieman et al.7
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Figure 2. Bargraph showing the effect of MK-801 (MK) alone or in combination with the antipsychotic drugs clozapine
(CLZ) or haloperidol (HAL) on the glutamate and serotonin output in rat PFC. Antipsychotic drugs were given
systemically (CLZ, 1 and 5 mg(kg; HAL 1 mg/kg) or locally, by reverse dialysis at the stated concentrations. Redrawn
from data in López-Gil et al.10
tracellular responses and/or b) local filed
potentials in the chloral hydrate anes-
thetized rats. These variables permit to ex-
amine cellular and population responses, re-
spectively, to drug administration. A full
account of the procedures used can be found
in Kargieman et al.6,7 and Celada et al.8
Histological experiments. The effects of
PCP and clozapina on PFC function were
also examined by using the expression of the
immediate early gene c-fos as a marker of
neuronal activity. This was conducted using
double in situ hybridization, labeling c-fos
mRNA with radioactive oligonucleotides
and the cellular phenotype (glutmatergic or
GABAergic neurons) with non-radioactive
oligonucleotides directed respectively to-
wards the vesicular glutamate transporter 1
(vGLuT1) pr the GABA-synthesizing en-
zyme GAD65/67 (glutamate acid decarboxy-
lase). See Kargieman et al.6,7 for details.
Microdialsyis experiments. These experi-
ments were aimed at examining the effect of
NMDA receptor antagonists and/or antipsy-
chotic drugs on the in vivo release of neuro-
transmitters in PFC: serotonin (5-HT),
dopamine (DA) and glutamate, as an index
of the activity of these neuronal groups in
response to drug administration. A full de-
scription of microdialysis procedures can be
found in Amargós-Bosch et al.9, López-Gil
et al.10,11
Data analysis. The effects of drugs on the
different variables used in the different stud-
ies (neurotransmitter concentrations, neu-
ronal discharge rate, power of cortical oscil-
lations, neuronal numbers, etc) have been
assessed by one- or two-way ANOVA for
independent or repeated measures, as ap-
propriate. Student’s t-tests have also been
used. Data are expressed as means ± SEM.
Statistical significance has been set at the
95% level (two-tailed).
Results
Effects of PCP on neuronal
activity in PFC. Reversal by
antipsychotic drugs
PCP induces a marked disruption of the
activity of the PFC in the rat, increasing and
decreasing the activity of 45% and 33% of
the pyramidal neurons recorded, respective-
ly (22% of the neurons were unaffected)6,12.
Concurrently, PCP markedly reduced corti-
cal synchrony in the delta frequency range
(0.3-4 Hz) as assessed by recording local
field potentials. The subsequent administra-
tion of the antipsychotic drugs haloperidol
and clozapine reversed PCP effects on pyra-
midal cell firing and cortical synchroniza-
tion6
Histological studies showed that PCP in-
creased c-fos expression in PFC pyramidal
neurons, an effect prevented by the admin-
istration of clozapine. PCP also enhanced
c-fos expression in the centromedial and
mediodorsal (but not reticular) nuclei of the
thalamus, suggesting the participation of
enhanced thalamocortical excitatory in-
puts6,7.
Effects of DOI on neuronal
activity in PFC. Reversal by
antipsychotic drugs
Similarly to PCP, DOI markedly disrupts
cellular and network activity in the rat PFC.
DOI altered pyramidal discharge in mPFC
(39% excited, 27% inhibited, 34% unaffect-
ed; n = 51)12. In all instances, DOI concur-
rently reduced low frequency oscillations
(0.3-4 Hz; power spectrum: 0.25 ± 0.02 and
0.14 ± 0.01 μV2 in basal conditions and
after 50-300 μg/kg i.v. DOI, respectively; n
= 51). Moreover, DOI disrupted the tempo-
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ral association between active phase of local
field potentials (LFP) and pyramidal dis-
charge8. Both effects were reversed by
M100907 (5-HT2A receptor antagonist) and
were not attenuated by thalamic lesions,
supporting an intracortical origin of the ef-
fects of DOI. 
As also observed for PCP, the alteration
of low frequency oscillations induced by
DOI was significantly reversed by the an-
tipsychotic drugs haloperidol (0.1-0.2
mg/kg i.v.) and clozapine (1 mg/kg i.v.)8.
Effects of NMDA-R antagonists
on neurotransmitter release in
PFC. Reversal by antipsychotic
drugs
The systemic, but not local (in PFC), ad-
ministration of the NMDA-R antagonists
PCP, ketamine and MK-801 increased the in
vivo 5-HT release in PFC9,10. Further inves-
tigations with MK-801 indicated that it also
produced a large increase in the efflux of
glutamate10, possibly as a neurochemical
correlate of the increase in pyramidal cell
activity seen with NMDA-R6,13.
Interestingly, whereas the local application
of MK-801 could not increase glutamate ef-
flux, both the local (in PFC) and systemic ad-
ministration of clozapine were able to reverse
the increased glutamate efflux induced by
systemic MK-801 administration10, suggest-
ing an intracortical action of clozapine. Fur-
ther studies examining the likely receptors
affected by clozapine suggest interactions
with 5-HT2A, 5-HT1A and _1-adrenoceptors
present in PFC pyramidal cells11. However,
despite 5-HT1Aeceptors in PFC appear nec-
essary for the atypical antipsychotic-induced
increase in cortical (PFC) dopamine re-
lease14, they play a minor role in the actions
of MK-801 to modulate dopamine release15.
Discussion
Despite the widespread use of NMDA re-
ceptor antagonists as pharmacological models
of schizophrenia, their neurobiological basis
of action is still poorly known. Neuroimaging
studies indicate that a sub-anesthetic dose of
ketamine increases the activity of the pre-
frontal cortex (PFC) in human volunteers16. In
experimental animals, NMDA receptor antag-
onists such as MK-801 or PCP increase neu-
ronal activity6, 13,17. Recent observations also
indicate that NMDA receptor antagonists and
5-HT2A receptor agonists produce a marked
loss of slow oscillations in PFC6,8 reflecting a
disruption of the function of cortical net-
works, which possibly reflects the psy-
chotomimetic properties of these compounds.
This effect is accompanied by a marked ex-
pression of the immediate early gene c-fos in
pyramidal (but not GABAergic) neurons. The
differential effect of PCP in pyramidal and
GABAergic neurons is consistent with a pref-
erential blockade of NMDA receptors in
GABAergic neurons18, subsequently leading
to pyramidal cell disinhibition. However,
since thalamic neurons also expressed c-fos, it
cannot be discarded that PCP can also act in
subcortical areas, this leading to an activation
of thalamocortical inputs. 
The increased PFC activity observed in
electrophysiological experiments is also
paralleled by an increased neurotransmitter
release in PFC9-11,15,19,20. This likely reflects
the activation of local and extended neu-
ronal networks, including the activation of
PFC descending afferents to the monoamin-
ergic midbrain nuclei (raphe nuclei and ven-
tral tegmental area) which contain the cell
bodies of serotonergic and dopamienrgic
neurons, respectively.
Interestingly, the above effects produced
by NMDA receptor antagonists (and –when
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examined– by 5-HT2A receptor agonists),
such as increased pyramidal neuron activity,
loss of cortical synchrony, increased c-fos ex-
pression and increased neurotransmitter re-
lease, are antagonized or reversed by classical
(haloperidol) and atypical (clozapine) an-
tipsychotic drugs. This suggests that the
above alterations in PFC function are inti-
mately related to schizophrenia. One interest-
ing observation is that both the local and sys-
temic administration of antipsychotic drugs
were able to antagonize the drug-induced
PFC abnormalities, supporting that antipsy-
chotric drugs normalize cortical function by a
local action in PFC, yet some differences
exist between haloperidol and clozapine
when antagonizing MK-801 effects on sero-
tonin and glutamate release. This may reflect
a distinct interaction of classical and atypical
drugs with monoamine receptors in PFC
which is possibly related to the distinct activi-
ty of both drugs on negatrive/cognitive symp-
toms. Overall, the above observations suggest
that the normalization of PFC function by an-
tipsychotic drugs is related to their therapeu-
tic activity in schizophrenia.
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